Moderna Upgrades 2026 Revenue Guidance Following Positive Phase 3 Cancer Vaccine Results

Moderna (MRNA) has raised its full-year 2026 revenue growth guidance to a range of 15% to 25%, up from previous estimates of up to 10%. This upward revision is driven by strong global demand for its updated COVID-19 vaccine, mNEXSPIKE, and expanded international supply agreements. The company also reported significant clinical success in oncology, with Phase 3 data for Intismeran autogene showing a 42% reduction in the risk of melanoma recurrence or death when used alongside Merck's Keytruda. This milestone highlights Moderna's ability to leverage its mRNA platform beyond respiratory vaccines into high-value cancer treatments. To support this transition, management is emphasizing cost discipline, having reduced expected 2026 research expenses by $200 million. The company aims to build a competitive moat through proprietary bioinformatic algorithms that link patient sequencing data directly to individualized manufacturing processes.

4 articles from 2 sources · updated

Coverage